Literature DB >> 26823044

Prognostic factors for survival after hepatic resection of early hepatocellular carcinoma in HBV-related cirrhotic patients.

Qian Zhu1, Bo Yuan2, Guo-Liang Qiao3, Jian-Jun Yan4, Yun Li1, Rui Duan1, Yi-Qun Yan5.   

Abstract

OBJECTIVE: The study aimed to identify clinico-pathologic factors that predict survival in early hepatocellular carcinoma (HCC) patients with hepatitis B virus (HBV)-related cirrhosis undergoing liver resection.
METHODS: A population-based cohort was investigated to identify cirrhotic patients with confirmed early HCC (tumor size≤5cm and absence of nodal involvement, metastases, or major vascular invasion) after hepatic resection at the Eastern Hepatobiliary Surgery Hospital (Shanghai, China) from April 2005 and November 2010 using the Surveillance, Epidemiology, and End Results (SEER) database. These patients were studied retrospectively in terms of their clinical characteristics and prognostic factors. Predictors for survival were evaluated using Kaplan-Meier methods and Cox proportional hazards models. Besides, a simple prognostic scoring system was proposed to stratify these patients.
RESULTS: Of 537 (2.6% of all HCC patients in this period) cirrhotic patients with early HCC identified who had underwent liver resection, 87% were male. Median tumor size was 2.9cm, and 67% of patients had tumors>2cm. Following hepatic resection, overall median and 5-year survival were 75 months and 58%, respectively. Tumor size>2cm (hazard ratio [HR]=1.56), multifocality (HR=1.34), non-anatomic resection (HR=1.44) and vascular invasion (HR=2.03) were associated with worse prognosis (P<0.05). Moreover, these patients could be further stratified into 4 distinct prognostic groups based on the prognostic scoring system developed.
CONCLUSION: Tumor size>2cm, multifocality, non-anatomic resection and vascular invasion may be used to stratify HBV-related cirrhotic patients with early HCC after resection. Besides, these data also indicate that pathologic staging is important even in small HCC.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26823044     DOI: 10.1016/j.clinre.2015.12.007

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  6 in total

1.  HCRP1, ID4 and Glypican-3: an optimal panel of biomarkers for diagnosis of hepatocellular carcinoma.

Authors:  Shujian Ge; Dan Wang; Beibei Lv; Shuping Yang; Chunmei Liu; Bin Xu; Chunming Zhao; Yejun Qin; Jiawen Xu
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

2.  Short- and Long-Term Outcomes After Hepatectomy in Elderly Patients with Hepatocellular Carcinoma: An Analysis of 229 Cases from a Developing Country.

Authors:  Danijel Galun; Aleksandar Bogdanovic; Marko Zivanovic; Marinko Zuvela
Journal:  J Hepatocell Carcinoma       Date:  2021-03-23

Review 3.  Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective.

Authors:  Danijel Galun; Dragana Mijac; Aleksandar Filipovic; Aleksandar Bogdanovic; Marko Zivanovic; Dragan Masulovic
Journal:  J Pers Med       Date:  2022-01-24

4.  Sub-Classification of Cirrhosis Affects Surgical Outcomes for Early Hepatocellular Carcinoma Independent of Portal Hypertension.

Authors:  Er-Lei Zhang; Jiang Li; Jian Li; Wen-Qiang Wang; Jin Gu; Zhi-Yong Huang
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

5.  Prognostic factors in patients with HBV-related hepatocellular carcinoma following hepatic resection.

Authors:  Narongsak Rungsakulkij; Wikran Suragul; Somkit Mingphruedhi; Pongsatorn Tangtawee; Paramin Muangkaew; Suraida Aeesoa
Journal:  Infect Agent Cancer       Date:  2018-06-08       Impact factor: 2.965

6.  Quantitative analysis of multiphase magnetic resonance images may assist prediction of histopathological grade of small hepatocellular carcinoma.

Authors:  Shuping Weng; Xuru Xu; Yueming Li; Chuan Yan; Jianwei Chen; Rongping Ye; Yuemin Zhu; Liting Wen; Jinsheng Hong
Journal:  Ann Transl Med       Date:  2020-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.